General Information of Drug (ID: DMD2L1U)

Drug Name
OBI-888
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D59OTG

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Globohexaosylceramide (Globo H) TT4UXTG NOUNIPROTAC Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03573544) This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of OBI Pharma.